AOD 9604 weight loss

AOD 9604 was marketed and developed as an anti-obesity drug. The rodent data was striking. The human data was not. Here's what the clinical trials actually showed, what users report, and how to think about diet when running a protocol.

The Metabolic Pharmaceuticals Phase IIb trial

The pivotal clinical trial for AOD 9604 weight loss was conducted by Metabolic Pharmaceuticals and reported in 2007. The trial enrolled obese adults (BMI 30–40) and randomized them to receive oral AOD 9604 at one of several dose levels or placebo, with dosing continuing for 12 weeks. The primary endpoint was change in body weight at 12 weeks relative to placebo.

The trial did not meet this endpoint. The AOD 9604 groups lost approximately 2.6 kg on average over 12 weeks, while the placebo group lost approximately 0.8 kg — a real difference, but not the clinically significant weight loss Metabolic Pharmaceuticals needed to justify a Phase III program. On the strength of that result, the company wound down the obesity program and pivoted to other indications.

Why the human data underperformed the animal data

AOD 9604 performed very well in preclinical obesity models. Obese mice lost meaningful fat mass in two- to three-week studies, and the fat loss was concentrated in visceral depots. Several factors are thought to explain why that did not translate cleanly to humans:

• Oral bioavailability. The Phase IIb trial used oral AOD 9604 because that was the commercial goal — a pill for obesity would be far more valuable than an injectable. But AOD 9604's oral bioavailability is very low, so even at doses of roughly 1 mg/kg per day, systemic exposure was modest.
• Species differences in adipose signaling. The receptor pathways through which AOD 9604 stimulates lipolysis may be more robust in rodents than in humans.
• Trial duration. 12 weeks is a short window for chronic metabolic interventions. A longer trial might have shown progressive effect — but the Phase IIb was the company's opportunity to justify further investment, and the result did not clear that bar.

AOD 9604 weight loss reviews and user reports

The user-reported experience with AOD 9604 weight loss in the peptide community is meaningfully different from the clinical trial experience, probably because non-clinical protocols almost always use the injectable route at higher effective systemic exposures. Common themes in AOD 9604 weight loss reviews include:

• Slow, steady recomposition over 8–12 weeks rather than rapid scale weight loss
• Visible reduction in waist circumference and abdominal fat disproportionate to scale changes
• No meaningful change in appetite or energy levels
• Best results when combined with caloric deficit and resistance training
• Minimal reports of dramatic transformations — AOD 9604 is rarely described as a "wonder drug"

These reports are anecdotal by nature. The more controlled datasets — preclinical rodent studies and the Phase IIb human trial — remain the most reliable frame for what to expect.

AOD 9604 diet plan considerations

Because AOD 9604 does not suppress appetite, diet is a larger variable for this peptide than it is for GLP-1 drugs like semaglutide. Running AOD 9604 without dietary changes tends to produce minimal measurable results. A few principles apply:

1. Maintain a caloric deficit. AOD 9604 mobilizes stored fat, but the body will not meaningfully reduce fat stores without a net energy gap. Most users structure protocols around a 300–500 kcal/day deficit.
2. Moderate carbohydrate intake. High insulin states suppress lipolysis, which may blunt AOD 9604's primary effect. Protocols often pair dosing with lower-carbohydrate meal structures, though the incremental benefit is not well characterized.
3. Dose before fasted activity. Morning dosing, 30–60 minutes before fasted cardio or low-intensity activity, aligns AOD 9604's peak effect with an already-elevated lipolytic state.
4. Protect lean mass with adequate protein. Resistance training and a minimum of ~1.6 g/kg/day protein intake help ensure the scale loss is fat rather than muscle.

AOD 9604 weight loss before and after

For a more detailed timeline of what AOD 9604 results typically look like at 4, 8, and 12 weeks, see the dedicated AOD 9604 before and after page and the results timeline. In short: modest but real fat loss, concentrated in the abdomen, with the clearest changes visible on photos rather than the scale.

Honest summary

If your goal is dramatic scale weight loss, AOD 9604 is not the best tool available in 2026. GLP-1 agonists like semaglutide and dual-agonists like tirzepatide produce 15–22% body weight reductions in clinical trials — an order of magnitude larger than AOD 9604's Phase IIb result. If your goal is targeted fat loss without appetite suppression, GI side effects, or muscle loss, AOD 9604 occupies a narrower but real niche. Set expectations accordingly.

Frequently asked questions